Recent Updates
Recently added Catalysts
ICCC Positive Sentiment

ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus

Key Takeaway: ImmuCell Corporation is set to hold a conference call on January 9, 2026, to discuss its strategic shift towards the First Defense® product line and away from Re-Tain®. The call will also cover unaudited sales results for Q4 and the full year 2025. The company aims to improve cattle health and productivity with its products.
Price reaction · baseline $6.35 (2026-01-06 close) · hit pre-market · 2 other ICCC headline(s) in the window, move may be shared
day 0 close · peak
-1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Strategic focus shift towards First Defense® is promising.
  • Upcoming conference call will provide insights into sales results.
  • Company aims to enhance cattle health and productivity.

Full Press Release Details

PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) --ImmuCell Corporation (Nasdaq: ICCC)(“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, plans to conduct a conference call with investors on Friday, January 9, 2026 at 9:00 AM ET.
The Company first announced a strategic change in focus in favor of theFirst Defense®product line and away fromRe-Tain®on December 24, 2025. The Company will also discuss its unaudited topline sales results for the fourth quarter and full year ended December 31, 2025, which will be announced after the market closes on Thursday, January 8, 2026.
Conference Calls:The Company is planning to host a conference call on Friday, January 9, 2026 at 9:00 AM ET to discuss its strategic shift toFirst Defense®and away fromRe-Tain®as well as its 2025 unaudited topline sales results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until January 16, 2026, at (855) 669-9658 (toll free) or (412) 317-0088 (international), utilizing replay access code #6043808.
The Company is planning to release its full, unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, February 25, 2026 and is planning to host a conference call on Thursday, February 26, 2026 at 9:00 AM ET to discuss these results. Interested parties can access that conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until March 5, 2026, at (855) 669-9658 (toll free) or (412) 317-0088 (international), utilizing replay access code #2017737.
About ImmuCell:ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve cattle health and productivity. ImmuCell manufactures and marketsFirst Defense®, providingImmediate Immunity™ to newborn dairy and beef calves. Press releases and other information about the Company are available at:http://www.immucell.com.
Contacts: Olivier te Boekhorst, President and CEOTimothy C. Fiori, Chief Financial OfficerImmuCell Corporationinvestor.relations@immucell.com
Joe Diaz, Robert Blum and Joe DorameLytham Partners, LLCiccc@lythampartners.com

Frequently Asked Questions

When is the ImmuCell conference call scheduled?

The conference call is scheduled for January 9, 2026, at 9:00 AM ET.

What will be discussed during the conference call?

The call will cover the strategic shift to First Defense® and Q4 sales results.

How can I access the conference call?

Dial (844) 855-9502 for toll-free access or (412) 317-5499 internationally.

What is the focus of ImmuCell's strategic change?

ImmuCell is shifting its focus towards the First Defense® product line.

When will the full financial results be released?

The full financial results will be released on February 25, 2026.

Last updated: Jan 7, 2026